Third Rock Ventures GP II, L.P.
CIK 1614061 · last filed 2021-09-17
Third Rock Ventures GP II, L.P. is a corporate insider who has filed 8 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for JNCE, was dated Sep 17, 2021. Across all open-market trades the lifetime net is −$46.3M, making them a net seller over the disclosed history. The firm reports its address in Boston, MA. 50 SEC filings were submitted jointly with Mark J Levin.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MYOK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
29 NEWBURY STREET, 3RD FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. (JNCE) Delisted | 10%+ Owner | 5,746,609 | $1.88 | $10.80M | -$652.6K | 3 | 2021-09-17 |
| MyoKardia, Inc. (MYOK) Delisted | 10%+ Owner | 4,885,104 | — | — | -$45.69M | 3 | 2017-09-29 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 4,742,916 | $8.68 | $41.17M | $0 | 1 | 2015-11-13 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | 10%+ Owner | 12,475,191 | $68.49 | $854.43M | $0 | 1 | 2015-08-19 |
Recent Filings
8 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-09-17 | Jounce Therapeutics, Inc. (JNCE) Delisted | Other (J) | −10,500,000 | $0 | EDGAR |
| 2021-03-15 | Jounce Therapeutics, Inc. (JNCE) Delisted | Other (J) | −7,500,000 | $0 | EDGAR |
| 2020-11-19 | Jounce Therapeutics, Inc. (JNCE) Delisted | Sell (S) | −90,000 | -$652.6K | EDGAR |
| 2017-09-29 | MyoKardia, Inc. (MYOK) Delisted | Other (J) | −10,000,000 | $0 | EDGAR |
| 2017-09-12 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −1,106,250 | -$45.69M | EDGAR |
| 2016-12-01 | MyoKardia, Inc. (MYOK) Delisted | Other (J) | −4,250,000 | $0 | EDGAR |
| 2015-11-13 | Sage Therapeutics, Inc. (SAGE) Delisted | Other (J) | −8,340,140 | $0 | EDGAR |
| 2015-08-19 | Global Blood Therapeutics, Inc. (GBT) Delisted | Conv (C) | +59,518,815 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.